Company Profile
Alterity Therapeutics Stock Price, News & Analysis
- Ticker:
- ATHE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
4.56 USD (+4.35%)
Close
Last updated: August 6, 2026
1.46M USD
Market cap
Why the stock is moving
Following the latest company update, “Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference”, ATHE closed up 4.35% at $4.56 on Aug 6, 2026. The move occurred in the trading session associated with this conference / presentation update.
Company overview
Business overview
Alterity Therapeutics is a neuroscience company focused on neurodegenerative disease, especially disorders with alpha-synuclein pathology. Its story is built around trying to address difficult CNS diseases through disease-modifying biology.
Geographic Base and Sector Classification
Alterity is headquartered in Australia and listed in the U.S. market. It sits in small-cap neuroscience biotechnology.
Business Model Characteristics
The company depends on translational validation, clinical progress, and capital support. Investors usually watch early data and whether the biology can create a compelling neurodegeneration thesis.
Position Within the Biotechnology Landscape
Alterity occupies a specialized neurodegeneration niche within biotech. It is catalyst-sensitive because the market needs evidence that the platform can matter in CNS disease.
Future catalysts
Alterity’s catalysts are ATH434 and the neurodegeneration / iron-biology story, with any clinical update that can re-rate the name quickly. The company is still very much a proof-of-concept story.
Recent news
- 01
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Source: Alterity Therapeutics
- 02
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Source: Alterity Therapeutics
- 03
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Source: Alterity Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alterity Therapeutics (ATHE)?
Alterity Therapeutics (ATHE) most recently closed at 4.56 USD, a +4.35% move versus the previous session.
What is the market cap of Alterity Therapeutics (ATHE)?
Alterity Therapeutics currently has a market capitalization of 1.46M USD on BioPharmSignal.
What does Alterity Therapeutics do?
Alterity Therapeutics is a neuroscience company focused on neurodegenerative disease, especially disorders with alpha-synuclein pathology. Its story is built around trying to address difficult CNS diseases through disease-modifying biology.
On which exchange is ATHE stock listed?
Alterity Therapeutics (ATHE) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is proof-of-concept?
The company is still very much a proof-of-concept story.
Which conditions is Alterity Therapeutics targeting with proof-of-concept?
Alterity Therapeutics is associated with neuroscience based on its company overview and current catalyst commentary.
How does Alterity Therapeutics describe recent progress with proof-of-concept?
The company is still very much a proof-of-concept story.
What is Alterity?
Alterity Therapeutics is a neuroscience company focused on neurodegenerative disease, especially disorders with alpha-synuclein pathology.